This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Manning R, et al. Comment on “Market exclusivity for drugs with multiple orphan approvals (1983–2017) and associated budget impact in the US”. Pharmacoeconomics. 2020. https://doi.org/10.1007/s40273-020-00975-7.
Socal MP, Parasrampuria S, Anderson GF. Modifying the criteria for granting orphan drug market exclusivity. Value Health. 2020;23(11):1470–6. https://doi.org/10.1016/j.jval.2020.08.004.
Padula WV, Parasraumpuria S, Socal M, Conti RM, Anderson GF. Market exclusivity for drugs with multiple orphan approvals (1983–2017) and the associated budget impact in the US. Pharmacoeconomics. 2020;38:1115–21. https://doi.org/10.1007/s40273-020-00934-2.
Hakim A, Ross JS. Obstacles to the adoption of biosimilars for chronic diseases. J Am Med Assoc. 2017;317(21):2163–4.
Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273–86.
The authors were supported by an unrestricted grant from Arnold Ventures Foundation to Johns Hopkins University to conduct this investigation.
Conflicts of Interest/Competing Interests
William V. Padula, Sonal Parasrampuria, Mariana P. Socal, Rena M. Conti, and Gerard F. Anderson have no conflicts of interest that are directly relevant to the content of this letter.
Consent to Participate
Consent for Publication
Availability of Data and Material
About this article
Cite this article
Padula, W.V., Parasrampuria, S., Socal, M.P. et al. Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”. PharmacoEconomics 38, 1375–1376 (2020). https://doi.org/10.1007/s40273-020-00973-9